CorMedix reports Q2 2026 results, flags REZZAYO filing and DefenCath supply deal
CorMedix expects to submit an sNDA for expanded REZZAYO use in Q3 2026 and signed a new dialysis supply agreement, while maintaining full-year revenue guidance.
SEC filing